DOCSLIB.ORG

Recent Advancement in Using Genetic Engineering for Curing Deadly Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recent Advancement in Using Genetic Engineering for Curing Deadly Diseases IOSR Journal of Biotechnology and Biochemistry (IOSR-JBB) ISSN: 2455-264X, Volume 6, Issue 2 (Mar. – Apr. 2020), PP 11-17 www.iosrjournals.org Recent Advancement in Using Genetic Engineering for Curing Deadly Diseases 1 2 Kamal Murtala Farouq, Abdulaziz Umar Kurya, Corresponding Author: Kamal Murtala Farouq 1Sharda University, Greater Noida, (U.P)- India. School of Engineering and Technology; Department of Genetic Engineering. 2School of Life and Allied Health Sceinces, Glocal University, Saharanpur, (U.P) - India. Abstract: CAR T-cell remedy is a “precision medicine” treatment, which means remedy that is tailored to person sufferers. It also belongs to a brand new group of most cancers treatments known as immunotherapy. In CAR T Cell remedy, a person’s T-cells which might be a number of the body’s maximum essential immune cells are taken from their blood, and then infused into the man or woman’s bloodstream. As of late, one of the most encouraging novel malignancy treatments has been the improvement of illusory antigen receptor CAR T cells. Their best model is focusing on the B cell lineage explicit surface antigen CD19, But CARs allow T-cells to locate and kill most cancers-carrying cells, that may otherwise be tough to perceive. Once within the bloodstream, CAR T-cells maintain to multiply, and this is why the treatment is every now and then called a “living drug.”In one tisagenlecleucel trial, eighty two % of the 79 children with ALL who obtained the treatment had been in remission 3 months after the infusion; at 18 months, the general survival bill become 70%. In every other trial, 40% of 93 adults with diffuse, big B-cell lymphoma showed a “whole response” a year after the treatment. CARs permit T-cells to detect and kill most cancers-wearing cells, which can otherwise be difficult to become aware of, however carry a totally serious disturb known as cytokine open syndrome, in which what's every so often called a “typhoon” of cytokine proteins flood into the bloodstream because of T- cells at paintings. CAR T cells are much less powerful for continual lymphocytic leukemia. This assessment will summarize the concept of CAR-based immunotherapy and current scientific trial interest and could in addition speak some of the in all likelihood future demanding situations dealing with CAR-modification T cellular cures. Despite the truth that the significance of this techniques, a series of complications has been discovered together with cytokine open syndrome, blood stress, fever, and possible brain infection, and Patients have to be closely monitored for at the least a month after infusion, and many are admitted to medical institution for this tracking duration. Keywords T cell · Gene modification, chimeric antigen receptor, Cancer, immunotherapy ----------------------------------------------------------------------------------------------------------------------------- ---------- Date of Submission: 10-03-2020 Date of Acceptance: 24-03-2020 ----------------------------------------------------------------------------------------------------------------------------- ---------- I. Introduction CAR T-cell remedy is a “precision medicine” remedy, meaning treatment that is tailor-made to individual patients. The idea of the chimeric antigen receptor (CAR; also known as T-cell bodies or chimeric immune receptors) changed into at the start defined over 15 years ago by means of Zelig Eshhar and associates running on the Weissman Institute in Israel. The technique became based totally upon the concept of expressing novel receptors on the T cellular surface that could allow the T cellular to pick out intact protein antigens present at the surface of a target cell. T cells usually recognize peptide antigens which might be supplied in association with most important histocompatibility complex (MHC) proteins via the target cell. However, one well-documented tumor escape mechanism is the modulation or down-regulation of MHC on the surface of the tumor cell which there by effectively renders the tumor “invisible” to T cells, since binding of the T cell receptor to peptide-MHC is a pre-requisite for T cell Vector function .The direct recognition of protein antigens through a CAR would then make the tumor cell “visible” to T cell immune surveillance once more. Moreover, the use of a targeting system that functions independently of MHC means that the CAR can be used in a generic manner rather than having the restrictions that are imposed by the use of T cell receptor (TCR) approaches where the specific receptor is only suitable for patients expressing a specific MHC. In addition, CARs can substantially broaden the range of antigens recognizable by T cells to include carbohydrate and glycolipid tumor antigens that are not within the scope of TCR-based recognition. Consequently, these factors make the use of CARs highly attractive for adoptive gene-modified T cell therapy. The reader is also directed to other highly relevant and recent reviews of CAR T cell biology and clinical application and focused reviews detailing novel directions of CAR T cell therapy approaches. In CAR T Cell theraphy, a person’s T-cells which are among the DOI: 10.9790/264X-0602011117 www.iosrjournals.org 11 | Page Recent Advancement in Using Genetic Engineering for Curing Deadly Diseases body’s most important immune cells are taken from their blood, and then infused into the person’s bloodstream, however in recent years, one of the most promising novel cancer therapies has been the development of chimeric antigen receptor CAR) T cells . Their most successful example is targeting the B cell lineage-specific surface antigen CD19, CAR stands for “chimeric antigen receptor,” which is the greater genetic count delivered to the T-cells. This method detects and kills most cancers-carrying cells that may in any other case be tough to identify. Once within the bloodstream, CAR T-cells continue to multiply, and this is why the treatment is now and again called a “residing drug.” Moreover, numerous cell parts of CAR T cell treatment stay cloud. In cerebrum tumors, CAR T cells face extra obstructions, as the dealing of insusceptible cells to the mind is firmly controlled and penetration of resistant cells into the tumor center just as their practical industriousness might be hindered because of the profoundly immunosuppressive tumor microenvironment. Current theories of CAR T cell tumor penetration examples, multiplication, and intratumoral movement depend on low-goals strategies, (for example, positron discharge tomography or bioluminescence imaging), ex vivo examinations, or in vitro tests, blocking rehashed investigation of individual cell conduct and tumor reactions in subtleties. The most striking accomplishment of CAR T cells has been accomplished in CD19+ B cell malignancies. Huge numbers of these semis fluid hematological malignancies live in the bone marrow, a specialty effectively available for intravascular T cells. In strong CD19+ tumors, Such as PCNSL, CAR T cells face 3 significant, extra hindrances: blocked movement toward the tumor, restricted entrance into the tumor, and a profoundly immunosuppressive tumor microenvironment, none of which have been envisioned in vivo at single-cell goals previously. Furthermore, CAR T cell preliminaries have come up short on the likelihood to over and again evaluate the point by point cell elements at precisely the same tumor site. CAR T-cell management has shown some very promising effects within the remedy of blood cancers as nicely. In one tisagenlecleucel trial, 82 percent of the 79 children with ALL who acquired the treatment were in remission 3 months after the implantation; at year and a 1/2, the overall persistence charge was 70 percent. In any other, 40 percentage of ninety three grown with diffuse large B-cell lymphoma verified a "total response" a year after the remedy. The two preliminaries were single-arm and both were bolstered by Novartis, the Swiss-based pharmaceutical organization that fabricates and has the patent for Kymriah. Most preclinical investigations of CAR T cells have utilized human CAR T cells. In any case, a few human cytokines need action on murine receptors, (for example, human IFN-γ, human GM-cerebrospinal liquid (CSF), or human IL-3 on murine receptors) and the other way around, (for example, murine IL-6 on human receptors). Current clinical preliminaries utilize both intracranial and i.v. utilization of CAR T cells to treat mind tumors, as the ideal course of conveyance stays indistinct. In a few preclinical tumor models (counting cerebrum tumors), provincial infusion has prompted before, CAR T cell actuation, higher viability, and longer industriousness contrasted and i.v. infusion. In any case, intracerebral infusion in patients with symptomatic mind tumors conveys a raised procedural hazard contrasted and i.v. application. Besides, a case report has as of late been distributed of a patient experiencing fundamental DLBCL with secondary, intracerebral lymphoma sign, which totally relapsed after i.v. hostile to CD19 CAR T cell infusion, recommending a conceivably positive impact of i.v. Vehicle T cell conveyance in CNS lymphoma .CAR T cells have been appeared to successively contact and kill a few tumor cells, with quicker development of an IS and increasingly fast separation of tumor cells contrasted and TCR-intervened cytotoxicity. Along these lines, while applying cytotoxic capacity, CAR T cell speed may display higher intratumoral speeds. In any case, the most energizing about these outcomes is that the patients who took an interest in these examinations were inert to or had backslid on various occasions in the wake of getting chemotherapy or potentially bone marrow transplant. "Vehicle Ts have opened up another treatment choice for us for kids who are generally untreatable," says Donna Wall, pediatric hematologist and area leader of the bone and marrow transplant program at Sick Kids Hospital. "We're unquestionably observing child and generally dither utilizing the fix word that we had definitely no different alternatives for." Moreover, CAR T-cellular remedy is called a “one-time remedy” as soon as the cells are in your body, they’re there to stay.
Load more

Recommended publications
  • Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy
    Current Hematologic Malignancy Reports (2019) 14:47–55 https://doi.org/10.1007/s11899-019-0498-6 STEM CELL TRANSPLANTATION (R MAZIARZ, SECTION EDITOR) Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy Stacie Ittershagen1 & Solveig Ericson1 & Lamis Eldjerou1 & Ali Shojaee1 & Eric Bleickardt1 & Manisha Patel1 & Tetiana Taran1 & Oezlem Anak2 & Charlene Hall1 & Mimi Leung1 & Deborah Roccoberton1 & Florence Salmon2 & Miriam Fuchs2 & Vadim Romanov1 & David Lebwohl1 Published online: 21 January 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review We describe the significant technological leap from bench to bedside that was achieved through a strong academic-industry collaboration between dedicated clinicians and researchers at the University of Pennsylvania, the Children’s Hospital of Philadelphia, and Novartis to commercialize the chimeric antigen receptor T cell (CAR-T) therapy tisagenlecleucel (CTL019; Kymriah®; Novartis Pharma AG, Basel, Switzerland). Recent Findings Tisagenlecleucel was the first CAR-T therapy and the first gene therapy to receive US Food and Drug Administration approval in 2017, with an initial indication for pediatric and young adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia, followed by approval in May 2018 for a second indication in adult patients with r/r diffuse large B cell lymphoma. Subsequent approvals in the European Union, Switzerland, and Canada soon followed. Summary The tisagenlecleucel success story represents the development and commercialization of a first-of-its-kind personal- ized cellular therapy with a manufacturing process that supports commercial production and ongoing global clinical trials in a growing number of countries. Keywords Acute lymphoblastic leukemia (ALL) .
    [Show full text]
  • Oncologic Drugs Advisory Committee Briefing Document
    Tisagenlecleucel (CTL019) FDA Advisory Committee Briefing Document Novartis 12-Jul-2017 ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel (CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION Page 1 Tisagenlecleucel (CTL019) FDA Advisory Committee Briefing Document Novartis 12-Jul-2017 Table of contents Table of contents .................................................................................................................2 List of tables ........................................................................................................................4 List of figures ......................................................................................................................6 List of abbreviations ............................................................................................................8 1 Executive summary ...........................................................................................................10 1.1 Tisagenlecleucel (CTL019) ...................................................................................10 1.1.1 Targeted indication................................................................................10 1.1.2 Unmet medical need for r/r B-cell ALL................................................10 1.1.3 Mechanism of action.............................................................................11 1.1.4 Manufacturing process
    [Show full text]
  • Cancer Immunotherapy Comes of Age and Looks for Maturity ✉ Amanda Finck1, Saar I
    COMMENT https://doi.org/10.1038/s41467-020-17140-5 OPEN Cancer immunotherapy comes of age and looks for maturity ✉ Amanda Finck1, Saar I. Gill1 & Carl H. June 1,2 As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportu- 1234567890():,; nities and challenges for the future. Improving the natural immune system through immune checkpoint blockade interference Advances in the understanding of basic immunology have ushered in two major approaches for cancer therapy over the past 10 years. The first is checkpoint therapy to augment the function of the natural immune system. The second uses the emerging discipline of synthetic biology and the tools of molecular biology and genome engineering to create new forms of biological structures, engineered viruses and cells with enhanced functionalities (Fig. 1). Trastuzumab, the monoclonal antibody targeting HER2, was the first recombinant antibody to be commercially approved, in 1997. However, over the past 10 years, a paradigm shift in cancer therapy occurred with the addition of inhibitors of the immune checkpoint blockade (ICB), CTLA-4 and PD-1, to the clinics. The first to be approved was the anti-CTLA-4 inhibitor ipilimumab for metastatic melanoma in 2011. More than a dozen types of cancer are now treated with ICBs. Perhaps most surprising to the field is that lung cancer can now be treated with PD-1 (CD279) and CTLA-4 (CD152) antagonists as a component of first line therapy. 10 years ago, the consensus among thoracic oncologists was that the solution for lung cancer was inhibitors of oncogene-driven signaling pathways and the field had dismissed the notion that lung cancer would be an immunologically responsive tumor.
    [Show full text]
  • Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives
    viruses Review Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives Roman P. Labbé 1,2,*, Sandrine Vessillier 2 and Qasim A. Rafiq 1 1 Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK; q.rafi[email protected] 2 Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC), Blanche Lane, Potters Bar, South Mimms EN6 3QG, UK; [email protected] * Correspondence: [email protected] Abstract: Lentiviral vectors have played a critical role in the emergence of gene-modified cell thera- pies, specifically T cell therapies. Tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta) and most recently brexucabtagene autoleucel (Tecartus) are examples of T cell therapies which are now commercially available for distribution after successfully obtaining EMA and FDA approval for the treatment of blood cancers. All three therapies rely on retroviral vectors to transduce the therapeutic chimeric antigen receptor (CAR) into T lymphocytes. Although these innovations represent promis- ing new therapeutic avenues, major obstacles remain in making them readily available tools for medical care. This article reviews the biological principles as well as the bioprocessing of lentiviral (LV) vectors and adoptive T cell therapy. Clinical and engineering successes, shortcomings and future opportunities are also discussed. The development of Good Manufacturing Practice (GMP)- compliant instruments, technologies and protocols will play an essential role in the development of LV-engineered T cell therapies. Citation: Labbé, R.P.; Vessillier, S.; Rafiq, Q.A. Lentiviral Vectors for T Keywords: CAR; T cell; lentivirus; viral vector; bioprocessing; manufacture Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.
    [Show full text]
  • Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma: Clinical Report
    CADTH OPTIMAL USE REPORT Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma: Clinical Report PROSPERO REGISTRATION NUMBER: CRD42018103201 Service Line: Optimal Use Version: Volume 8, Issue 3c Publication Date: January 2019 Report Length: 158 Pages Cite As: Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma: Clinical Report. Ottawa: CADTH; 2019 Jan. (CADTH optimal use report; vol.8, no.3c). ISSN: 1927-0127 (English only) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • KYMRIAH Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Administer 0.6 to 6.0 x 108 CAR-positive viable T cells These highlights do not include all the information needed to use intravenously. (2.2) KYMRIAH safely and effectively. See full prescribing information for KYMRIAH. ---------------------DOSAGE FORMS AND STRENGTHS--------------------- ® • Pediatric and Young Adult B-cell ALL (up to 25 years of age) KYMRIAH (tisagenlecleucel) suspension for intravenous infusion 6 Initial U.S. Approval: 2017 A single dose of KYMRIAH contains 0.2 to 5.0 x 10 CAR-positive viable T cells per kg of body weight for patients 50 kg or less, or 0.1 to 2.5 x 108 CAR- WARNING: CYTOKINE RELEASE SYNDROME and positive viable T cells for patients more than 50 kg, suspended in one to three NEUROLOGICAL TOXICITIES patient-specific infusion bag(s) for IV infusion. (3) See full prescribing information for complete boxed warning. • Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma A single dose of KYMRIAH contains 0.6 to 6.0 x 108 CAR-positive viable T • Cytokine Release Syndrome (CRS), including fatal or life-threatening cells suspended in one to three patient-specific infusion bag(s) for IV infusion. reactions, occurred in patients receiving KYMRIAH. Do not (3) administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with -------------------------------CONTRAINDICATIONS----------------------------- tocilizumab or tocilizumab and corticosteroids. (2.3, 2.4, 5.1) None. (4) • Neurological toxicities, which may be severe or life-threatening, can ------------------------WARNINGS AND PRECAUTIONS----------------------- occur following treatment with KYMRIAH, including concurrently • Hypersensitivity Reactions: Monitor for hypersensitivity reactions during with CRS.
    [Show full text]
  • Kymriah (Tisagenlecleucel)
    Kymriah (tisagenlecleucel) Policy Number: Current Effective Date: MM.02.036 August 1, 2019 Lines of Business: Original Effective Date: HMO; PPO; QUEST Integration June 1, 2018 Precertification: Place(s) of Service: Required, see section IV Inpatient I. Description The spontaneous regression of certain cancers (e.g., renal cell carcinoma, melanoma) supports the idea that a patient’s immune system can delay tumor progression and, on rare occasions, can eliminate tumors altogether. These observations have led to research into various immunologic therapies designed to stimulate a patient’s own immune system. Adoptive immunotherapy is a method of activating lymphocytes and/or other types of cells for the treatment of cancer and other diseases. Cells are removed from the patient, processed for some period of time, and then infused back into the patient. Tisagenlecleucel For individuals who are 3 to 25 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia who receive tisagenlecleucel, the evidence includes multiple single-arm prospective trials. Relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. The pivotal single-arm trials reported an 83% response rate (measured by complete response or complete remission with incomplete blood count) in heavily pretreated patients. All patients who achieved a complete remission or complete remission with incomplete blood count were also minimal residual disease- negative, which is predictive of survival in acute lymphoblastic leukemia patients. After a median follow-up of 4.8 months, the median duration of response was not reached. The observed benefits seen with tisagenlecleucel were offset by a high frequency and severity of adverse reactions.
    [Show full text]
  • The Cytokine Release Syndrome and Associated Arrhythmias
    Review Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias Cesar Simbaqueba Clavijo1, Maria Patarroyo Aponte2, Peter Kim3, Anita Deswal3, Nicolas L. Palaskas3, Cezar Downloaded from http://meridian.allenpress.com/innovationsjournals-JIPO/article-pdf/doi/10.36401/JIPO-20-10/2552894/10.36401_jipo-20-10.pdf by University of California user on 02 August 2020 Iliescu3, Eiman Jahangir4, Eric H. Yang5, Raphael E. Steiner6, Juan Lopez-Mattei3 1Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 2Department of Cardiology, University of Texas Health System, Memorial Hermann Hospital, Houston, Texas 3Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas 4Department of Cardiology, Vanderbilt University Medical Center, Vanderbilt, Tennessee 5UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, California 6Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas Address correspondence to Juan Lopez-Mattei, MD ([email protected]) Source of Support: None. Conflict of Interest: None. Received: March 24, 2020; Accepted: May 28, 2020 Simbaqueba Clavijo CS, Aponte MP, Kim, P, Deswal A, Palaskas NL, Iliescu C, Jahangir E, Yang, EH, Steiner RE, Lopez-Mattei J. Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias. J Immunother Precis Oncol. 2020; 3:000–000. DOI: 10.36401/JIPO-20-10. & Innovative Healthcare Institute ABSTRACT In recent years, cancer treatment has evolved, and new therapies have been introduced with significant improvement in prognosis. The immunotherapies stand out owing to their efficacy and remission rate.
    [Show full text]
  • Kymriah (Tisagenlecleucel) (Intravenous) Document Number: IC-0319 Last Review Date: 10/30/2018 Date of Origin: 09/19/2017 Dates Reviewed: 09/2017, 06/2018, 11/2018
    Kymriah (tisagenlecleucel) (Intravenous) Document Number: IC-0319 Last Review Date: 10/30/2018 Date of Origin: 09/19/2017 Dates Reviewed: 09/2017, 06/2018, 11/2018 I. Length of Authorization Coverage will be provided for one treatment course (1 dose of Kymriah) and may not be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [Pharmacy Benefit]: N/A B. Max Units (per dose and over time) [Medical Benefit]: B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) 1 billable unit (1 infusion of up to 250 million car-positive viable t-cells) Large B-Cell Lymphoma 1 billable unit (1 infusion of up to 600 million car-positive viable t-cells) III. Initial Approval Criteria Coverage is provided in the following conditions: Patient does not have an active infection or inflammatory disorder; AND Patient has not received live vaccines within 6 weeks prior to the start of lymphodepleting chemotherapy and will not receive live vaccines until immune recovery following Kymriah treatment; AND Patient has been screened for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines prior to collection of cells (leukapheresis); AND Prophylaxis for infection has been followed according to local guidelines; AND Healthcare facility has enrolled in the Kymriah REMS and training has been given to providers on the management of cytokine release syndrome (CRS) and neurological toxicities; AND Proprietary & Confidential © 2018 Magellan Health, Inc. Patient has not received prior
    [Show full text]
  • Kymriah Chimeric Antigen Receptor T Cell Therapy
    Subject: Chimeric Antigen Receptor T cell Therapy (CAR-T Cell Therapy): Original Effective Kymriah (Tisagenlecleucel) Date: 4/12/2018 Molina Clinical Policy (MCP) Number: Revision Date(s): 3/11/2019 MCP-317a Review Date: 3/11/2019 MCPC Approval Date: 3/11/2019 DISCLAIMER This Molina clinical policy is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website . The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina clinical policy document and provide the directive for all Medicare members.
    [Show full text]
  • BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs
    BLA 125646 Tisagenlecleucel FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novartis Pharmaceuticals Corporation DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We bring the BLA for tisagenlecleucel, a first- in-class product, with the applicant's proposed indications to this Advisory Committee to gain the Committee’s insights and opinions. The background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory committee meeting. 1 BLA 125646 Tisagenlecleucel Table of Contents 1. PROPOSED INDICATION.................................................................................................. 8 2. EXECUTIVE SUMMARY ..................................................................................................
    [Show full text]
  • Kymriah, INN-Tisagenlecleucel
    28 June 2018 EMA/485563/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Kymriah International non-proprietary name: tisagenlecleucel Procedure No. EMEA/H/C/004090/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Administrative information Name of the medicinal product: Kymriah Applicant: Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland Active substance: tisagenlecleucel International Non-proprietary Name/Common tisagenlecleucel Name: Pharmaco-therapeutic group other antineoplastic agents (ATC Code): (Not yet assigned) Indicated for the treatment of: Therapeutic indications: Paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Pharmaceutical form: dispersion for infusion Strength: 1.2 x 106 – 6 x 108 cells Route of administration: intravenous use Packaging: bag (ethylene vinyl acetate) Package size: 1-3 bags Assessment report EMA/CHMP/443047/2018 Page 2 Table of contents 1.45T Background information on the procedure 45T .............................................. 8 1.1.45T Submission of the dossier45T ...................................................................................... 8 1.2.45T Steps taken for the assessment of the product 45T ......................................................
    [Show full text]